Loading...
Loading...
According to a research report published this morning, Dougherty has downgraded Hologic
HOLX to Neutral, and lowered PT from $26 to $20.
In the report, Dougherty commented, "Hologic reported F2Q:12 sales of $471.2MM (vs. our $473.0MM; Street $474.0MM) and EPS of $0.33 (vs. our $0.34; Street $0.33)—we note that the Breast Health business was surprisingly weaker than expected at $218.6MM (vs. our $225.4MM; Street $222.0MM). We would have expected a healthier Breast Health business, given the Dimensions Tomosynthesis Year-2 rollout. Ultimately, we ponder whether the Gen-Probe transaction is a smoke-screen for a weaker base business."
Hologic closed yesterday at $19.11.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in